drugset / Trial / NCT03410030
Trial of Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM)
Phase 1/2
Completed
27 enrolled
HonorHealth Research Institute
Barts Cancer Institute · collabCancer Research UK · collabCold Spring Harbor Laboratory · collabImaging Endpoints · collabLustgarten Foundation · collabPrinceton University · collabSalk Institute for Biological Studies · collabStand Up To Cancer · collabTranslational Genomics Research Institute · collabUniversity of Arizona · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to see if a treatment regimen with a combination of paclitaxel protein bound (also known as nab-paclitaxel), gemcitabine, and cisplatin when given with high dose Ascorbic Acid will be safe and effective in individuals with untreated metastatic pancreatic cancer.
Timeline
- Start
- 2017-12-15
- Primary completion
- 2021-09-14
- Completion
- 2022-01-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | — | — |
| Subject | Gemcitabine | Small molecule | — | — |
| Subject | Paclitaxel | Small molecule | — | — |
| Subject | Vitamin C | Other / unclassified | 25 g | Intravenous |
| Subject | Vitamin C | Other / unclassified | 37.5 g | Intravenous |
| Subject | Vitamin C | Other / unclassified | 56.25 g | Intravenous |